Hims & Hers Health Inc. (HIMS) has turned from a buzzworthy startup into a serious player in the U.S. telehealth market. From prescription hair loss treatments to mental health care, Hims stock has become a unique tech-health crossover in the investing world. But in 2025, with a shifting economy and growing competition, investors want to know — is Hims stock still a buy?
Let’s break down everything you need to know before investing in HIMS — the risks, the upside, and what could make this stock a standout or a slip-up in the health-tech space.
💼 What Does Hims & Hers Do?
Hims & Hers Health (Ticker: HIMS) is a direct-to-consumer telehealth company offering virtual medical consultations and prescription delivery for:
- Hair loss and skin care
- Sexual health
- Mental health
- Primary care
Unlike traditional providers, Hims offers low-cost, private consultations via its app or website, making healthcare more accessible to younger, tech-savvy users.
The company earns through subscription-based models, allowing for strong monthly recurring revenue (MRR).
📈 Hims Stock Performance: A 2025 Snapshot
As of mid-2025, HIMS stock is trading around the $9–$11 range, with:
- YTD growth: +18%
- 52-week range: $6.50 – $12.10
- Market Cap: ~$2.5 billion
- P/E Ratio: N/A (still unprofitable)
While not yet profitable, the company has narrowed losses, improved gross margins, and guided toward breakeven in late 2025.
📉 Risks of Investing in Hims Stock
1. Intense Competition
The telehealth space is booming, but it’s crowded. Teladoc, Amazon (One Medical), and even CVS Health are building similar platforms. Hims needs to retain its brand edge and loyal millennial user base to stay ahead.
2. Regulatory Concerns
Online prescriptions and remote diagnoses are under growing scrutiny by health regulators. Any tightening of rules could slow growth or increase costs.
3. Profitability Timeline
Despite strong revenue growth, Hims remains unprofitable. Investors should watch quarterly reports closely for signs of positive EBITDA or net income targets being hit.
📊 Why Hims Stock Still Has Upside
1. Massive TAM (Total Addressable Market)
Telehealth is expected to be a $450B+ market by 2030, and Hims is one of the few brands targeting wellness and aesthetics along with core health.
2. Brand Loyalty
Unlike clinical rivals, Hims has built a lifestyle brand. Its packaging, subscription simplicity, and influencer partnerships make it the “Glossier of healthcare.”
3. High Gross Margins
Even with marketing costs, the company consistently delivers gross margins above 70% — a rare win in the health-tech space.
🧠 Expert Tip: Is HIMS a Growth or Speculative Play?
HIMS is a speculative growth stock — suitable for investors with:
- A 3–5 year horizon
- Higher risk appetite
- Belief in digital health adoption
It may not be ideal for dividend seekers or conservative portfolios, but the risk-reward in 2025 is more attractive than in its SPAC debut years.
📈 Hims vs. Other Telehealth Stocks
| Company | 2025 YTD Return | Profitability | Focus Area |
|---|---|---|---|
| Hims & Hers | +18% | Near Breakeven | Wellness, Mental Health |
| Teladoc Health | -6% | Unprofitable | Chronic Conditions |
| Amazon (One Medical) | +12% | Profitable | Primary Care |
Hims offers niche appeal and direct-to-consumer access that others lack — a key moat if they can scale profitably.
🧠 Bonus Tips for Investing in Hims Stock
- Track Earnings Reports – Watch gross margins, user growth, and profit guidance.
- Watch FDA Announcements – Regulations on digital prescriptions could impact revenue.
- Compare With Peers – Benchmark Hims against Teladoc and Amazon for positioning.
- Follow Insider Activity – Insider buying could hint at bullish sentiment.
- Evaluate Brand Momentum – Hims is as much a brand play as a health stock.
FAQs
Is Hims stock a good investment in 2025?
Hims stock is a speculative buy for long-term growth investors focused on the digital health space.
Does Hims stock pay dividends?
No, HIMS does not pay dividends. It reinvests revenue into growth and expansion.
Is Hims profitable?
Not yet. The company has improved margins and may hit profitability by the end of 2025.
Where can I buy Hims stock?
HIMS trades on the New York Stock Exchange under the ticker “HIMS” and is available via any major brokerage.
Who are Hims’ biggest competitors?
Key rivals include Teladoc, Amazon’s One Medical, and traditional pharmacies entering telehealth.
READ ALSO :
Dow Jones Stock Markets in 2025: What Futures & Oil Prices Reveal
👤 Author Bio Box
Written by the Swipywiro Team
Swipywiro.com delivers professional, U.S.-focused stock and crypto insights with clear research, SEO optimization, and zero fluff. Follow us on Twitter @swipywiro.
⚠️ Financial Disclaimer
This content is for educational purposes only and should not be considered financial advice. Always consult a licensed financial advisor before investing.